Toward Unified AI Drug Discovery with Multimodal Knowledge

Author:

Luo Yizhen12ORCID,Liu Xing Yi1,Yang Kai1,Huang Kui13,Hong Massimo12,Zhang Jiahuan1,Wu Yushuai1ORCID,Nie Zaiqing14ORCID

Affiliation:

1. Institute for AI Industry Research (AIR), Tsinghua University, Beijing, China.

2. Department of Computer Science and Technology, Tsinghua University, Beijing, China.

3. School of Software and Microelectronics, Peking University, Beijing, China.

4. Beijing Academy of Artificial Intelligence (BAAI), Beijing, China.

Abstract

Background: In real-world drug discovery, human experts typically grasp molecular knowledge of drugs and proteins from multimodal sources including molecular structures, structured knowledge from knowledge bases, and unstructured knowledge from biomedical literature. Existing multimodal approaches in AI drug discovery integrate either structured or unstructured knowledge independently, which compromises the holistic understanding of biomolecules. Besides, they fail to address the missing modality problem, where multimodal information is missing for novel drugs and proteins. Methods: In this work, we present KEDD, a unified, end-to-end deep learning framework that jointly incorporates both structured and unstructured knowledge for vast AI drug discovery tasks. The framework first incorporates independent representation learning models to extract the underlying characteristics from each modality. Then, it applies a feature fusion technique to calculate the prediction results. To mitigate the missing modality problem, we leverage sparse attention and a modality masking technique to reconstruct the missing features based on top relevant molecules. Results: Benefiting from structured and unstructured knowledge, our framework achieves a deeper understanding of biomolecules. KEDD outperforms state-of-the-art models by an average of 5.2% on drug–target interaction prediction, 2.6% on drug property prediction, 1.2% on drug–drug interaction prediction, and 4.1% on protein–protein interaction prediction. Through qualitative analysis, we reveal KEDD’s promising potential in assisting real-world applications. Conclusions: By incorporating biomolecular expertise from multimodal knowledge, KEDD bears promise in accelerating drug discovery.

Funder

National key Research and Development Program of China

Publisher

American Association for the Advancement of Science (AAAS)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Large language models for medicine: a survey;International Journal of Machine Learning and Cybernetics;2024-08-19

2. Multi-Modal CLIP-Informed Protein Editing;2024-07-28

3. Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond;BioMedInformatics;2024-06-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3